You're staring at a balance sheet. But maybe it's a client's. Now, maybe it's your company's. Maybe you're studying for the CPA exam and the coffee has worn off. Either way, you've landed on the patent line item and the question hits: *wait — is this a current asset?
Short answer: almost never. But the "why" matters more than the answer itself.
What Is a Patent, Really?
A patent is a legal right. It gives the holder exclusive control over an invention — typically for 20 years from the filing date. Here's the thing — granted by a government. During that window, nobody else can make, use, sell, or import the patented thing without permission.
That exclusivity has value. Sometimes enormous value. Pharmaceutical companies build entire business models around patent portfolios. Tech giants buy thousands of patents just to play defense Practical, not theoretical..
But here's the accounting reality: a patent is an intangible asset. No physical substance. No warehouse space needed. Just legal enforceability and future economic benefit.
How Patents Show Up on the Balance Sheet
If a company develops a patent internally — R&D, legal fees, filing costs — most of those costs get expensed as incurred under both GAAP and IFRS. That's why only certain direct costs after technological feasibility might be capitalized. And even then, it's narrow.
But if a company buys a patent? But the purchase price gets capitalized as an intangible asset. That's different. Same if they acquire a business and the purchase price allocation assigns value to patents.
Either way, once it's on the books, it sits under non-current assets — specifically, intangible assets. Right alongside trademarks, copyrights, customer lists, and goodwill.
Why It Matters: Current vs. Non-Current Classification
Classification isn't academic. It changes ratios. Practically speaking, it changes covenants. It changes how analysts see liquidity.
Current assets are expected to be:
- Converted to cash
- Sold
- Consumed ...within one year (or the operating cycle, if longer).
Think: cash, accounts receivable, inventory, prepaid expenses. Stuff that moves The details matter here..
Non-current assets? Long-term investments. Property, plant, equipment. Everything else. And intangible assets like patents.
The 20-Year Problem
A patent's legal life is 20 years from filing. Think about it: its useful life might be shorter — technology moves fast. But it's almost never less than a year. Unless you're buying a patent that expires next month (rare), it fails the current asset test by a mile It's one of those things that adds up..
So it gets amortized. Straight-line, typically. On the flip side, over its useful life. Not its legal life. That distinction matters.
How It Works: From Acquisition to Amortization
Let's walk through the lifecycle. Because this is where people get tripped up.
1. Initial Recognition
Company A buys Patent X for $2 million. Cash goes down. Intangible asset — Patent — goes up by $2 million. Simple That's the part that actually makes a difference..
But wait. What if they bought a portfolio? Now you need to allocate. Still, maybe Patent X is worth $1. 2M, Patent Y $600K, Patent Z $200K. That allocation drives amortization later. Get it wrong and you're misstating expense for years.
2. Determining Useful Life
Legal life = 20 years. Useful life = ?
Maybe the tech becomes obsolete in 7 years. Maybe a competitor designs around it in 5. Maybe regulatory changes kill the market in 3 Easy to understand, harder to ignore..
You amortize over the shorter of legal life or useful life. And you document your reasoning. Auditors will ask.
3. Amortization Expense
Straight-line is standard. $2M patent, 10-year useful life = $200K/year expense. Hits the income statement. Reduces the carrying value on the balance sheet The details matter here..
Journal entry:
Dr. Amortization Expense 200,000
Cr. Accumulated Amortization 200,000
After year 1, the patent shows at $1.8M net. After year 10, it's zero And that's really what it comes down to..
4. Impairment Testing
Here's where it gets interesting. Also, patents don't always generate the cash flows you expected. A standard changes. A drug fails Phase III. A lawsuit invalidates the claims.
Under GAAP (ASC 350), you test for impairment only when a triggering event occurs. Not annually. Triggers include:
- Significant adverse change in legal factors
- Change in business climate
- Current-period operating loss + history of losses
- Significant decline in market price
Basically the bit that actually matters in practice.
If impaired, you write down to fair value. IFRS (IAS 36) allows reversal. And — critically — you cannot reverse it later under GAAP. That loss hits earnings. Another reason classification matters.
5. Disposal or Expiration
Patent expires? Because of that, remove gross carrying amount and accumulated amortization. That's why fully amortized? No gain or loss usually.
Sell it before expiry? That's why compare proceeds to net book value. Gain or loss on disposal. Shows up in "other income/expense" typically Turns out it matters..
Common Mistakes / What Most People Get Wrong
Mistake 1: Confusing "Intangible" with "Current"
People hear "asset" and think "current.That said, " They see the patent has value now — licensing revenue, strategic apply — and assume it's liquid. It's not. Liquidity ≠ value The details matter here..
Mistake 2: Amortizing Over Legal Life Automatically
20 years is the default maximum. Not the default answer. That's aggressive accounting. But overstating life understates expense. If the useful life is 8 years, amortize over 8. Auditors hate it The details matter here..
Mistake 3: Capitalizing Internal R&D Costs
Under U.IFRS is slightly more permissive (IAS 38) but still strict. Period. R&D is expense. GAAP, you cannot capitalize internally generated patent costs (with very narrow exceptions for software). S. Don't capitalize the lawyer fees for your own patent application.
Mistake 4: Forgetting Impairment Triggers
Companies set up amortization schedules and forget them. That said, then a competitor launches a workaround. Even so, revenue drops. In practice, the patent's recoverable amount plunges. Worth adding: if you don't test, you're carrying inflated assets. That's a restatement waiting to happen Which is the point..
Mistake 5: Treating Patent Renewal Fees as Capital Expenditures
Annual maintenance fees to keep a patent alive? Expense them. They don't extend the legal life beyond 20 years. They don't enhance future benefits. They're just the cost of holding the right. Recurring cost = operating expense.
Practical Tips / What Actually Works
1. Build a Patent Register
Track every patent: acquisition date, cost, legal life, useful life, amortization method, accumulated amortization, jurisdiction, renewal dates. So your auditors will thank you. In practice, update it quarterly. One spreadsheet. So will your tax team It's one of those things that adds up..
2. Document Useful Life Assumptions
Write a memo. "Patent X covers Technology Y. Think about it: competitor Z has alternative approach expected to launch 2027. Useful life estimated at 6 years based on..." File it. Reference it in workpapers.
###3. Align Amortization with Revenue Patterns
Straight-line is the default, but rarely the most accurate. Because of that, if a patent protects a drug with front-loaded sales (peak revenue in years 1–3, then generic erosion), straight-line understates early expense and overstates late expense. Now, use the units-of-production or revenue-based method if you can reliably forecast output or sales tied directly to the patent. In practice, match expense to the economic benefit consumed. Document the forecast methodology rigorously — auditors will challenge the correlation The details matter here..
At its core, the bit that actually matters in practice And that's really what it comes down to..
4. Separate Defense Costs from Asset Costs
Litigation is expensive. Defending a patent (suing infringers, opposing challenges) is typically an operating expense — you’re protecting existing value, not creating new future benefits. Prosecuting new claims, filing continuations, or acquiring adjacent IP to build a thicket? That may qualify for capitalization if it demonstrably extends useful life or expands scope. The line is thin. Default to expense unless you have a contemporaneous memo from IP counsel linking the spend to a measurable life extension or scope expansion.
5. Model Tax vs. Book Differences Proactively
Book amortization (GAAP/IFRS) rarely matches tax amortization (IRC §197 — 15 years straight-line, mandatory). The spread creates a deferred tax liability (DTL) that grows for years. Don’t treat it as a plug. Track the temporary difference per patent. When impairment hits book but not tax (common — tax basis doesn’t impair), the DTL reverses partially. When you sell, the tax gain/loss calculation depends on adjusted tax basis, not book NBV. A patent register that tags each asset with both book and tax carrying values saves weeks of reconciliation at year-end Worth knowing..
Not obvious, but once you see it — you'll see it everywhere.
6. Stress-Test Terminal Value in M&A
In a purchase price allocation (PPA), patents often get the residual after working capital, tangibles, and customer relationships. What if the discount rate moves 100 bps? Because of that, run sensitivity analysis: What if the useful life is 2 years shorter? But that residual carries high risk. What if a key claim is invalidated? Now, if the goodwill impairment trigger moves from "unlikely" to "plausible" under reasonable downside scenarios, flag it in the integration memo. Boards hate surprises; CFOs hate restatements Not complicated — just consistent. Took long enough..
Conclusion
Patents sit at the intersection of law, strategy, and accounting — and that intersection is where value is either captured or leaked. Even so, the accounting rules (ASC 350, IAS 38) are rigid by design: they force discipline on assets that are inherently uncertain. Which means capitalize only what meets the threshold. Which means amortize over the economic life, not the legal maximum. Test for impairment when the business changes, not just when the calendar turns. Expense the maintenance, the defense, and the internal R&D without hesitation.
The companies that treat patent accounting as a compliance checkbox end up with bloated balance sheets, volatile earnings, and awkward auditor letters. The ones that build registers, document assumptions, align expense with economics, and bridge book-to-tax early turn IP accounting into a strategic lens — one that tells the CFO, the board, and the market exactly what the portfolio is worth, how long it will pay, and when the risk arrives.
A patent is a wasting asset with a legal shield. Account for it that way.
